Spondyloepimetaphyseal Dysplasia Krakow Type

1. Disease Information

Definition and overview

SEMDK is a Mendelian skeletal dysplasia within the spondyloepimetaphyseal dysplasia group, distinguished by the combination of severe vertebral, epiphyseal and metaphyseal abnormalities, rhizomelia and mesomelia with pronounced anterior bowing of long bones, severe primary immunodeficiency, and global developmental delay.[1][3][4][5][13] The condition has been described in two siblings from a consanguineous family, establishing it as a recessive immuno‑osseous dysplasia rather than a purely skeletal disorder.[1][10][13]

Key identifiers

• OMIM: 618162 – “Spondyloepimetaphyseal dysplasia, Krakow type; SEMDK”.[1][8][9]
• MONDO: MONDO:0032571 – “spondyloepimetaphyseal dysplasia, Krakow type”.[7][12]
• MedGen Concept ID: 1648323 – “Spondyloepimetaphyseal dysplasia, Krakow type”.[2][4]
• UniProt disease ID: DI‑05362 – “Spondyloepimetaphyseal dysplasia, Krakow type”.[11]
• KEGG disease: H02187 – “Spondyloepimetaphyseal dysplasia (includes SEMD Krakow type as a subtype)”.[14]

No dedicated ICD‑10/ICD‑11 or MeSH term has been identified; SEMDK is typically grouped under broader categories for congenital skeletal dysplasia and primary immunodeficiency in coding systems.[1][2][3]

Synonyms and alternative names

• Spondyloepimetaphyseal dysplasia, Krakow type (SEMDK).[1][3][4][5]
• Immunoosseous dysplasia, Krakow type.[5][13]
• Spondylo‑epi‑metaphyseal dysplasia, Krakow type.[13]

Source type

The core clinical and genetic information comes from an individual family case report (human clinical evidence; Csukasi et al., 2018, PMID:30232230) and is aggregated in disease‑level resources such as OMIM, MedGen, MalaCards, rarediseases.org, KEGG, UniProt and PanelApp.[1][3][4][5][10][11][12][13]

2. Etiology

Disease causal factors

Genetic cause

SEMDK is caused by homozygous germline missense mutation in SIK3 (salt‑inducible kinase 3), a serine/threonine protein kinase located on chromosome 11q23.3.[1][6][10][12]

• OMIM 618162 assigns a “number sign” to the phenotype, indicating causation by SIK3 mutation and notes autosomal recessive inheritance.[1]
• The reported pathogenic variant is NM_001366686.3(SIK3):c.559C>T, resulting in p.Arg187Cys in the canonical SIK3 isoform; the original case report described the same change as p.Arg129Cys in an alternative isoform.[1][6][10]
• ClinVar classifies NM_001366686.3(SIK3):c.559C>T (p.Arg187Cys) as pathogenic for SEMDK, with germline origin and single‑nucleotide variant type.[6]

SIK3 (HGNC:28980; OMIM:614776) encodes a member of the salt‑inducible kinase family involved in regulation of CREB‑dependent transcription and cartilage and bone growth plate function, providing a plausible mechanistic link to skeletal development and potentially immune cell function.[1][10][11]

No non‑genetic primary causes (environmental, infectious, toxic) have been implicated.[1][3][10]

Genetic risk factors

• Causal variant: Homozygous SIK3 c.559C>T (p.Arg187Cys/p.Arg129Cys) is the only variant reported to date in association with SEMDK.[1][6][10]
• Inheritance: Autosomal recessive; both affected siblings in the reported family were homozygous for the variant, with heterozygous carrier parents.[1][10][12]
• Allele frequency: The variant was absent from major population databases at the time of publication and is treated as private to the family; databases summarizing the case note no population frequency data.[1][6][10]
• Consanguinity: The original family was consanguineous, suggesting parental relatedness as a risk factor for homozygosity of a rare deleterious allele (human clinical evidence).[1][10][13]

No susceptibility loci or modifier genes have been described; the evidence base is limited to a single pedigree.[1][3][10]

Environmental risk factors

No specific environmental, lifestyle, occupational, or infectious risk factors have been linked to disease onset; the condition appears fully penetrant in the presence of biallelic SIK3 mutation.[1][3][10]

Protective factors

No genetic or environmental protective factors have been reported for SEMDK.[1][3][10]

Gene–environment interactions

No gene–environment interaction data are currently available for SEMDK.[1][3][10] Management recommendations emphasize minimizing infectious exposures due to underlying immunodeficiency, but this relates to prognosis rather than disease causation.[10]

3. Phenotypes

Available phenotype information is derived from the two affected siblings and summarized consistently across OMIM, MedGen, MalaCards, rarediseases.org and case‑based literature.[1][3][4][5][13]

Core skeletal phenotypes (symptoms/signs)

• Severe spondyloepimetaphyseal dysplasia: Involvement of vertebral bodies, epiphyses and metaphyses with marked growth plate abnormalities.[1][3][13]
• Type: Clinical signs/physical manifestations (radiographic and morphologic).
• Onset: Congenital/early infancy (radiographs abnormal from early life).[1][13]
• Severity: Severe, leading to disproportionate short stature.[1][3][13]
• Progression: Progressive bone deformity during growth.[1][3][13]
• Frequency: Present in all described affected individuals (2/2) – ~100% in known cases.[1][3][13]
• Quality of life impact: Major impairment of mobility, growth, and musculoskeletal function (inferred from severity of dysplasia).[1][3][13]

• Suggested HPO:

  • Spondyloepimetaphyseal dysplasia (HP:0002650).
  • Abnormal epiphysis morphology (HP:0010572).
  • Abnormal metaphysis morphology (HP:0000947).
  • Platyspondyly (HP:0000926).

• Rhizomelia and mesomelia with anterior bowing of limbs: Proximal and middle limb segment shortening and pronounced anterior bowing of long bones.[3][13]

• Type: Physical manifestations.
• Onset: Recognizable in infancy.[13]
• Severity: Marked limb deformity.[3][13]
• Progression: Structural; may worsen as growth proceeds (inferred).
• Frequency: Present in the reported siblings.[3][13]
• Quality of life impact: Limits ambulation; may require orthopedic support (inferred).[13]

• Suggested HPO:

  • Rhizomelia (HP:0008964).
  • Mesomelia (HP:0003027).
  • Bowing of long bones (HP:0003002).

• Severe short stature/dwarfism: Height markedly below age norms due to skeletal dysplasia.[1][3][13]

• Type: Symptom/clinical sign.
• Onset: Early childhood.[1][13]
• Severity: Severe (proportionate to skeletal involvement).[1][3]
• Progression: Persistent; likely worsens with age relative to peers.
• Frequency: Universal in affected siblings.[1][3][13]
• Quality of life impact: Functional limitations, psychosocial impact (inferred).
• Suggested HPO: Short stature (HP:0004322).

Immune and infection‑related phenotypes

• Severe immunodeficiency: Profound primary immunodeficiency with recurrent, severe infections.[1][3][4][5][10][13]
• Type: Clinical sign/laboratory abnormality.
• Onset: Early childhood, with severe infections occurring in infancy/early childhood.[1][10][13]
• Severity: Severe; one child reportedly died from infection‑related complications (human clinical evidence).[1][10][13]
• Progression: Persistent; no spontaneous remission described.[1][3][10]
• Frequency: Universal in reported cases.[1][3][10][13]
• Quality of life impact: Life‑threatening; major morbidity due to recurrent infections.[1][3][10][13]
• Suggested HPO:
  • Primary immunodeficiency (HP:0002721).
  • Recurrent infections (HP:0002719).
  • Recurrent respiratory infections (HP:0002205).

Neurodevelopmental phenotypes

• Global developmental delay: Delayed attainment of developmental milestones.[1][3][4][5][13]
• Type: Behavioral/neurological symptom.
• Onset: Recognized in infancy/early childhood.[1][13]
• Severity: Moderate to severe (inferred from description of “developmental delay”).[1][3]
• Progression: Persistent; no evidence for catch‑up.[1][3]
• Frequency: Present in both affected siblings.[1][3][13]
• Quality of life impact: Significant impact on independence and learning (inferred).
• Suggested HPO: Global developmental delay (HP:0001263).

Other possible features

Database summaries suggest involvement of endocrine and neurologic manifestations in the clinical spectrum, but detailed phenotyping beyond skeletal, immunological and developmental domains is limited in published sources.[3][10][13]

Quality‑of‑life and standardized patient‑reported outcome measures (EQ‑5D, SF‑36) have not been formally reported for SEMDK.[1][3][10]

4. Genetic/Molecular Information

Causal gene

• Gene: SIK3 (Salt‑Inducible Kinase 3).
• OMIM gene ID: 614776.[1]
• HGNC ID: 28980 (standard gene catalog; general knowledge).
• Cytogenetic location: 11q23.3.[1][6][10]
• SIK3 is a protein‑coding serine/threonine kinase of the AMPK family, implicated in regulation of CREB/CRTC transcription and endochondral bone growth.[1][10][11]

Pathogenic variants

• Reported variant: NM_001366686.3(SIK3):c.559C>T (p.Arg187Cys) – single‑nucleotide missense variant.[6][10]
• ClinVar classification: Pathogenic, germline.[6]
• Type: Missense SNV.[6]
• Disease association: Spondyloepimetaphyseal dysplasia, Krakow type.[6][10][12]
• Isoform notation: The original case report describes the same substitution as p.Arg129Cys in a shorter SIK3 isoform; OMIM notes this and links the variant to SEMDK.[1][10]
• Allele frequency: Not found in large population datasets at time of reporting, consistent with an ultra‑rare, private variant.[1][6][10]
• Functional consequence: The variant is inferred to be loss‑of‑function or hypomorphic, disrupting SIK3 kinase activity in growth plate chondrocytes and possibly immune cells.[1][10][11] This is inferred from the gene’s known role rather than direct biochemical data in SEMDK.

No other SIK3 variants or other genes have been definitively associated with SEMDK, and SIK3 remains the sole gene with moderate evidence for the phenotype in curated panels.[1][10][12]

Modifier genes and epigenetic information

No modifier genes or epigenetic alterations have been described for SEMDK.[1][3][10]

Chromosomal abnormalities

No chromosomal structural changes (aneuploidy, translocations, CNVs) are reported in association with SEMDK; the disease is due to a single missense variant in an otherwise structurally normal chromosome.[1][6][10]

5. Environmental Information

Published information and database summaries do not identify specific environmental, toxic, occupational, or lifestyle factors that contribute to SEMDK risk or severity.[1][3][10]

Given the primary immunodeficiency, clinicians recommend minimizing infectious exposures and using standard infection prophylaxis strategies, but this is supportive management rather than a disease cause.[10]

6. Mechanism / Pathophysiology

Ordered causal chain (with inferred steps noted)

1. Biallelic SIK3 missense mutation (c.559C>T, p.Arg187Cys) leads to altered SIK3 kinase structure and activity in growth plate chondrocytes and immune cells (inferred from kinase domain location and gene function).[1][6][10][11]
2. Impaired SIK3 signaling leads to dysregulation of CREB/CRTC‑dependent transcription and other downstream pathways controlling chondrocyte proliferation and hypertrophy (inferred from general SIK3 biology).[11]
3. Abnormal chondrocyte differentiation and endochondral ossification result in defective vertebral, epiphyseal and metaphyseal development, leading to spondyloepimetaphyseal dysplasia with rhizomelia, mesomelia and bowed limbs.[1][3][13]
4. Defective SIK3 function in immune cells (e.g., B/T lymphocytes) leads to impaired immune signaling and lymphocyte maturation, resulting in severe primary immunodeficiency with recurrent infections (inferred; human clinical evidence of immunodeficiency without detailed cellular work‑up).[1][3][10][13]
5. Chronic skeletal deformity and impaired growth plate function lead to severe short stature and musculoskeletal disability.[1][3][13]
6. Recurrent severe infections and immunodeficiency result in high morbidity and at least one early childhood death, defining the prognosis of SEMDK.[1][10][13]
7. Global developmental delay may result from a combination of systemic illness, possible direct CNS effects of SIK3 dysfunction, and musculoskeletal limitations (largely inferred; human clinical evidence for delay).[1][3][13]

Molecular pathways (inferred from SIK3 biology)

• SIK3 belongs to the AMPK‑related kinase family and regulates transcription via phosphorylation of CRTC and class IIa histone deacetylases, affecting CREB‑dependent gene expression in multiple tissues.[11]
• In cartilage, SIK3 is implicated in endochondral bone growth and growth plate maturation, linking it to pathways controlling chondrocyte hypertrophy and ossification (e.g., PTHrP–IHH axis, Wnt signaling) by modulation of transcription factors.[11][14]
• Direct mapping of SEMDK to specific curated pathways (e.g., KEGG, Reactome) has not yet been reported; KEGG lists SEMD (including Krakow type) as a heterogeneous group of dwarfing disorders associated with multiple genes.[14]

Suggested GO biological process terms:
- Endochondral bone morphogenesis (GO:0060350).
- Cartilage development (GO:0051216).
- Chondrocyte differentiation (GO:0030212).
- Immune system process (GO:0002376).

Cellular processes

• Chondrocyte proliferation and hypertrophy: SIK3 dysfunction is inferred to disturb normal growth plate chondrocyte proliferation and maturation, leading to disorganized columns and abnormal ossification.[11][14]
• Immune cell development and signaling: The severe immunodeficiency suggests disrupted lymphocyte function, possibly via altered transcriptional programs in B and T cells; however, specific defects (e.g., class‑switched memory B cells) have not been characterized.[1][3][10]

Suggested CL cell types:
- Growth plate chondrocyte (CL:0000138).
- Osteoblast (CL:0000120).
- B cell (CL:0000236).
- T cell (CL:0000084).

Protein dysfunction

• The disease‑causing variant lies in the N‑terminal kinase domain of SIK3, and a missense substitution of a conserved arginine is expected to perturb ATP binding or substrate interaction, causing reduced or aberrant kinase activity (inferred).[6][11]
• UniProt annotates SIK3 as a serine/threonine kinase with regulatory roles in transcription and metabolism, supporting the idea that missense mutation leads to loss‑of‑function or hypomorphic activity.[11]

Metabolic and biochemical changes

No direct metabolomic or biochemical profiling data are available for SEMDK; any changes are inferred to be downstream of disrupted growth plate biology and immune cell function.[1][3][10]

Immune system involvement

• Severe, recurrent infections and immunodeficiency are core features of SEMDK, indicating a major immune system involvement.[1][3][4][5][10][13]
• The specific immunologic defect (humoral, cellular, combined) has not been described in detail; published summaries simply report “severe immunodeficiency”.[1][3][5][10]

Suggested GO terms:
- Adaptive immune response (GO:0002250).
- Lymphocyte activation (GO:0046649).

Tissue damage mechanisms

• Skeletal tissues: Chronic mechanical stress on malformed bones leads to secondary joint damage and pain (inferred from general skeletal dysplasia pathology).[1][3][13]
• Immune system: Recurrent infections cause inflammatory damage in lungs and other organs; in the reported family, infection‑related complications contributed to mortality.[1][10][13]

Epigenetic, molecular profiling, and advanced technologies

No epigenetic, transcriptomic, proteomic, metabolomic, single‑cell, spatial transcriptomic or functional genomics studies are available for SEMDK specifically.[1][3][10][11] Studies of SIK3 in other contexts support its role in transcriptional regulation and cartilage biology, but these have not yet been integrated as disease‑specific multi‑omics in SEMDK.[11][14]

7. Anatomical Structures Affected

Organ‑level

Primary organs and systems:

• Axial skeleton (vertebral column): Platyspondyly and vertebral abnormalities.[1][3][13]
• Suggested UBERON: Vertebral column (UBERON:0002413).
• Appendicular skeleton (long bones and joints): Rhizomelic and mesomelic shortening; bowed long bones; abnormal epiphyses and metaphyses.[1][3][13]
• Suggested UBERON: Long bone (UBERON:0002445).
• Epiphysis of long bone (UBERON:0003840).
• Metaphysis of long bone (UBERON:0003841).
• Immune system organs: Likely involvement of lymphoid tissues (bone marrow, thymus, spleen, lymph nodes) associated with immunodeficiency, although specific organ pathology is not described.[1][3][10]
• Suggested UBERON: Spleen (UBERON:0002106); Thymus (UBERON:0002370); Lymph node (UBERON:0000029).

Secondary involvement:

• Respiratory system: Recurrent respiratory infections and pneumonia due to immunodeficiency.[1][10][13]
• Suggested UBERON: Lung (UBERON:0002048).
• Neurological system: Global developmental delay implies CNS functional involvement, though structural brain abnormalities are not reported.[1][3][13]

Tissue and cell level

• Tissues: Cartilage and bone (growth plate cartilage, subchondral bone) and lymphoid tissues.[1][3][10][13]
• Suggested UBERON: Hyaline cartilage (UBERON:0002414); Bone tissue (UBERON:0002481).
• Cells: Growth plate chondrocytes, osteoblasts, osteoclasts, and lymphocytes (B and T cells).[11][14]

Suggested CL terms:
- Chondrocyte (CL:0000138).
- Osteoblast (CL:0000120).
- Osteoclast (CL:0000121).
- B cell (CL:0000236).
- T cell (CL:0000084).

Subcellular level

Subcellular compartments relevant to SIK3:

• Cytoplasm and nucleus (location of SIK3 and its substrates).[11]
• Protein kinase complexes and transcriptional regulation machinery.[11]

Suggested GO cellular component terms:
- Cytoplasm (GO:0005737).
- Nucleus (GO:0005634).
- Protein kinase complex (GO:1902554).

Localization and lateralization

• Skeletal abnormalities are systemic and bilateral, affecting all limbs and the spine.[1][3][13]
• No lateralization (left–right asymmetry) has been reported.[1][3][13]

8. Temporal Development

Onset

• Age of onset: Congenital/early pediatric; skeletal abnormalities and growth impairment are evident from infancy, with immunodeficiency and developmental delay recognized in early childhood.[1][3][13]
• Onset pattern: Chronic and insidious; there is no acute onset event, but symptoms manifest as growth proceeds.[1][3][13]

Progression

• Disease stages: Not formally defined, but clinical course can be conceptualized as:
• Early stage: Recognition of skeletal dysplasia, growth failure, and early developmental delay.
• Intermediate stage: Progressive limb deformities, mobility limitations, and recurrent severe infections.
• Advanced stage: Severe musculoskeletal disability, recurrent life‑threatening infections, and possible early mortality.[1][10][13]
• Progression rate: Slowly progressive skeletal abnormalities; immunodeficiency manifests early with recurrent episodes.[1][3][10][13]
• Course pattern: Chronic, lifelong; no remission described.[1][3][10]

Duration and critical periods

• Disease appears lifelong, with significant morbidity and risk of early childhood death due to infection, based on the reported family.[1][10][13]
• Critical periods likely include infancy and early childhood when infections are frequent and skeletal growth is rapid, offering windows for early diagnosis and prophylactic interventions.[10][13]

9. Inheritance and Population

Epidemiology

• Prevalence and incidence: Not known; SEMDK is ultra‑rare, with only a single family described in detail and no registry‑based prevalence estimates.[1][3][4][5][10][13]
• Orphanet‑level estimates are not yet established for this specific subtype.[1][3]

Inheritance pattern

• Autosomal recessive: Both affected siblings were homozygous for the SIK3 variant, with heterozygous carrier parents in a consanguineous pedigree, consistent with autosomal recessive inheritance.[1][10][12]
• PanelApp and clinical genomic databases list SEMDK under autosomal recessive skeletal dysplasia conditions.[10][12]

Penetrance, expressivity, and other genetic features

• Penetrance: Appears complete within the reported family; all homozygous individuals were affected.[1][10]
• Expressivity: Limited data from two siblings suggest similar severity and phenotype, but overall expressivity is unknown.[1][3][10][13]
• Genetic anticipation, germline mosaicism, founder effects: No evidence for these phenomena; the variant is considered a private mutation in a single consanguineous family.[1][3][10]
• Carrier frequency: Unknown; given absence from population databases, carrier frequency is presumed extremely low.[1][6][10]

Population demographics

• The reported family appears to have origins consistent with the Krakow label, but detailed ethnicity and geographic distribution are not systematically documented; SEMDK is not known to be endemic in any region.[1][3][10][13]
• Sex ratio: With only two affected siblings, sex predilection cannot be established.[1][3][10][13]
• Age distribution: Manifestation in infancy and early childhood; adult cases have not been reported.[1][3][10][13]

10. Diagnostics

Clinical and laboratory evaluation

Key elements of diagnosis:

• Clinical suspicion: Disproportionate short stature with rhizomelic/mesomelic limb shortening, pronounced anterior bowing of long bones, vertebral flattening, severe immunodeficiency, and developmental delay.[1][3][4][5][13]
• Imaging: Skeletal survey with radiographs of spine and long bones revealing platyspondyly and epimetaphyseal abnormalities typical of SEMD, plus distinctive bowing and limb segment shortening.[1][3][13]
• Suggested RadLex concept: Skeletal survey; platyspondyly.
• Immune work‑up: Basic immunologic tests (immunoglobulin levels, lymphocyte subsets) are expected but not detailed in published summaries; diagnosis of “severe immunodeficiency” is clinical.[1][3][10][13]
• Developmental assessment: Standard neurodevelopmental evaluations to document global delay.[1][3][13]

No specific biochemical biomarkers have been validated for SEMDK beyond genetic testing.[1][3][6][10]

Genetic testing

Given the rarity and phenotypic overlap with other skeletal dysplasias, advanced genomic testing is central:

• Whole exome sequencing (WES): Used in the original family after PTH1R mutation was excluded, leading to identification of homozygous SIK3 missense variant.[1][10][13]
• Single‑gene or targeted panel testing: SIK3 is now included in skeletal dysplasia gene panels (e.g., Genomics England PanelApp skeletal dysplasia panel).[12]
• PanelApp lists SIK3 with moderate evidence for SEMDK, inheritance “biallelic (autosomal)”.[12]
• Clinical variant interpretation: ClinVar provides classification and basic annotations for NM_001366686.3(SIK3):c.559C>T (p.Arg187Cys).[6]

Chromosomal microarray, karyotyping, FISH, mitochondrial DNA analysis, and repeat expansion tests are not indicated in typical SEMDK work‑ups unless broader differential diagnoses are considered.[1][3][10]

Clinical criteria and differential diagnosis

No formal, society‑endorsed diagnostic criteria exist for SEMDK due to the very small evidence base.[1][3][10]

Differential diagnosis:

• Other forms of spondyloepimetaphyseal dysplasia (e.g., Isidor‑Toutain type, Maroteaux type), which may share skeletal features but lack severe immunodeficiency.[14][13]
• Other immuno‑osseous dysplasias (e.g., Schimke immuno‑osseous dysplasia), which combine skeletal dysplasia with immunodeficiency and can present similarly.[13]
• Primary immunodeficiency disorders without skeletal dysplasia.

Distinguishing features include the specific pattern of limb bowing, vertebral and epimetaphyseal involvement, and association with SIK3 mutation.[1][3][10][13][14]

Screening

No population screening programs exist for SEMDK.[1][3][10] Genetic testing is recommended for:

• Symptomatic individuals with compatible phenotype.
• At‑risk siblings in families with known SIK3 pathogenic variants (cascade testing).[10][12]

Newborn screening does not include SEMDK.[1][3][10]

11. Outcome / Prognosis

Survival and mortality

• Published information indicates severe morbidity and at least one early childhood death due to infection‑related complications in the reported family (human clinical evidence).[1][10][13]
• Formal survival rates, life expectancy estimates, and disease‑specific mortality statistics are not available given the extremely small case number.[1][3][10]

Morbidity and function

• Morbidity is substantial, driven by skeletal deformities, profound short stature, recurrent severe infections, and developmental delay.[1][3][4][5][10][13]
• Long‑term functional impairments include mobility limitations, dependence on caregivers, and vulnerability to serious infections.[1][3][10][13]

No standardized disability metrics (e.g., ICF coding) or quality‑of‑life scores (EQ‑5D, SF‑36, PROMIS) have been reported specifically for SEMDK.[1][3][10]

Disease course and complications

• Complications:
• Recurrent pneumonia and severe respiratory infections.[1][10][13]
• Orthopedic complications from limb deformities (e.g., joint contractures, pain, gait disturbance).[1][3][13]
• Recovery potential: Structural skeletal abnormalities are permanent; immunodeficiency may be partially mitigated by prophylactic measures and immunoglobulin replacement (inferred from immunodeficiency management principles).[10]

Prognostic factors

• Severity of immunodeficiency and frequency of infections are likely major determinants of survival and morbidity.[1][3][10][13]
• Access to aggressive infection prophylaxis and treatment may improve outcomes (clinical genomic database recommendation).[10]

No validated prognostic biomarkers or risk models exist for SEMDK.[1][3][10]

12. Treatment

Pharmacotherapy and supportive care

No disease‑specific curative pharmacologic therapy exists; management is supportive and extrapolated from principles of skeletal dysplasia and primary immunodeficiency.[1][3][10][13]

Key components (clinical genomic database and case‑based guidance):[10][13]

1. Infection prophylaxis and treatment
2. Early and aggressive antibiotic therapy for infections.[10][13]
3. Consideration of prophylactic antibiotics in high‑risk periods (inferred).

4. Suggested NCIT terms: Antibiotic Therapy (NCIT:C77209).

5. Immunoglobulin replacement

6. For patients with significant humoral immunodeficiency, intravenous or subcutaneous immunoglobulin may be considered (inferred from standard immunodeficiency care).[10]

7. Suggested NCIT: Immunoglobulin Replacement Therapy (NCIT:C15410).

8. Orthopedic management

9. Orthopedic interventions (bracing, corrective osteotomies) to manage limb deformities and improve function (inferred from skeletal dysplasia care).[13]

10. Suggested NCIT: Orthopedic Surgery Procedure (NCIT:C15273).

11. Physical and occupational therapy

12. To maximize mobility and function.[13]

13. Suggested NCIT: Physical Therapy (NCIT:C15429); Occupational Therapy (NCIT:C15432).

14. Developmental and educational support

15. Early intervention services for developmental delay.[1][3][13]

No specific pharmacogenomic data exist for SEMDK; standard antibiotic and immunoglobulin pharmacogenomics apply generically.[10]

Advanced therapeutics

• Gene therapy, cell therapy, RNA‑based therapies, targeted molecular therapies, immunotherapies: None have been developed or trialed specifically for SEMDK as of current literature.[1][3][10][12]
• The rarity of the condition and limited mechanistic detail have prevented disease‑specific clinical trials.[1][3][10]

Treatment outcomes and strategies

• Published outcomes are limited to the original family and case‑based descriptions, with variable infection control and severe skeletal morbidity.[1][10][13]
• Clinical genomic databases highlight awareness of SEMDK as a means to implement anti‑infectious prophylaxis and aggressive infection treatment, suggesting this may improve prognosis.[10]

No formal treatment algorithms or guidelines exist; treatment is individualized by multidisciplinary teams (pediatrics, immunology, orthopedics, rehabilitation).[1][3][10][13]

13. Prevention

Primary prevention

• Genetic counseling: For families with known SIK3 pathogenic variants, counseling can inform reproductive decisions and reduce recurrence risk through carrier testing.[10][12]
• Avoidance of consanguinity: In populations where consanguineous marriage is common, education about autosomal recessive risks may reduce likelihood of homozygous rare variants like SIK3 c.559C>T (inferred).[1][10][13]

Secondary prevention (early detection)

• Cascade genetic testing: Testing siblings and close relatives of affected individuals for SIK3 variants enables early diagnosis and monitoring.[10][12]
• Prenatal or preimplantation genetic diagnosis: Could be offered to carrier couples with known pathogenic SIK3 variants (inferred from standard Mendelian disease practice).[10][12]

No population‑level screening programs for SEMDK exist.[1][3][10]

Tertiary prevention

• Infection prophylaxis: Implementation of vaccination schedules, prophylactic antibiotics, and immunoglobulin replacement to prevent severe infections.[10]
• Orthopedic and rehabilitation interventions: To prevent secondary musculoskeletal complications (e.g., contractures, chronic pain).[13]

Public health and environmental interventions are not disease‑specific but align with general infection control and skeletal health measures.[10][13]

14. Other Species / Natural Disease

Taxonomy and orthologous genes

• SIK3 has orthologs in multiple species, including rodents; rat Sik3 is annotated with disease cross‑references to human SEMDK in rat gene databases (association by orthology, not natural disease).[15]
• NCBI Gene IDs and orthology relationships indicate evolutionary conservation of SIK3, but specific SEMDK‑like phenotypes have not been described in animals.[11][15]

Natural disease and comparative biology

• No naturally occurring SEMDK or identical immuno‑osseous dysplasia due to Sik3 mutation has been reported in companion animals or livestock.[1][3][15]
• Comparative pathology data are limited; however, conservation of SIK3 function in skeletal development across vertebrates suggests animal models could recapitulate aspects of human bone pathology (inferred).[11][15]

Zoonotic potential and cross‑species transmission are not applicable: SEMDK is a non‑infectious genetic disorder.[1][3][10]

15. Model Organisms

No dedicated SEMDK animal models have been reported in curated model organism databases, although Sik3 manipulation in rodents and other organisms has been used to study skeletal development in general.[11][15]

Model types and characteristics

• Genetic models (inferred):
• Sik3 knockout or knock‑in models in mice or rats would be expected to show growth plate and skeletal phenotypes, but detailed recapitulation of SEMDK’s combined skeletal and immunologic phenotype has not been documented.[11][15]
• Phenotype recapitulation:
• Existing Sik3 models (where studied) likely reflect aspects of bone growth defects but may not capture the full immunologic and neurodevelopmental spectrum observed in SEMDK.[11][15]
• Limitations:
• Lack of published data on immunodeficiency in Sik3 models limits their direct use for studying SEMDK’s immune component.[11][15]

Applications and resources

• SIK3 ortholog models can be used to investigate:
• Growth plate biology and chondrocyte maturation.
• Downstream signaling pathways of SIK3 in cartilage and immune cells.[11][15]

Model resources are referenced indirectly via orthologous gene annotations rather than disease‑specific repositories.[11][15]

Summary of Ontology and Evidence Mapping

• Disease ontology: MONDO:0032571 – Spondyloepimetaphyseal dysplasia, Krakow type.[7][12]
• Gene/protein: SIK3 (HGNC:28980; OMIM:614776).[1][10][11]
• Key HPO terms: Spondyloepimetaphyseal dysplasia (HP:0002650), Short stature (HP:0004322), Rhizomelia (HP:0008964), Mesomelia (HP:0003027), Bowing of long bones (HP:0003002), Primary immunodeficiency (HP:0002721), Recurrent infections (HP:0002719), Global developmental delay (HP:0001263).[1][3][4][5][13]
• GO biological processes: Endochondral bone morphogenesis (GO:0060350), Cartilage development (GO:0051216), Chondrocyte differentiation (GO:0030212), Immune system process (GO:0002376).[11][14]
• CL cell types: Chondrocyte (CL:0000138), Osteoblast (CL:0000120), B cell (CL:0000236), T cell (CL:0000084).[11][14]
• UBERON anatomical locations: Vertebral column (UBERON:0002413), Long bone (UBERON:0002445), Epiphysis of long bone (UBERON:0003840), Metaphysis of long bone (UBERON:0003841), Spleen (UBERON:0002106), Thymus (UBERON:0002370).[1][3][10][13]
• NCIT interventions: Orthopedic Surgery Procedure (NCIT:C15273), Physical Therapy (NCIT:C15429), Immunoglobulin Replacement Therapy (NCIT:C15410), Antibiotic Therapy (NCIT:C77209).[10][13]

Evidence types:

• Human clinical: Csukasi et al. 2018 (PMID:30232230) and case‑based reports summarized by OMIM, MedGen, MalaCards, Kauvery Hospital article.[1][3][4][10][13]
• Computational/aggregated: OMIM, MedGen, MalaCards, rarediseases.org, KEGG, UniProt, PanelApp, ClinVar, Clinical Genomic Database, rat gene databases.[1][2][3][5][6][10][11][12][14][15]
• Model organism/inferred: Sik3 ortholog annotations in rat and general SIK3 functional studies (not disease‑specific).[11][15]

Overall, SEMDK remains an extremely rare, recently defined immuno‑osseous dysplasia with a single known causative variant in SIK3, a very limited clinical evidence base, and largely inferred mechanistic and management frameworks.

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• HP:0002650 (2 mentions) - the report calls it "Spondyloepimetaphyseal dysplasia", "Key HPO terms: Spondyloepimetaphyseal dysplasia"; HP calls it Scoliosis**
• HP:0000947 (1 mention) - the report calls it "Abnormal metaphysis morphology"; HP calls it Dumbbell-shaped long bone
• HP:0008964 (2 mentions) - the report calls it "Rhizomelia"; HP calls it Nonprogressive muscular atrophy
• HP:0003002 (2 mentions) - the report calls it "Bowing of long bones"; HP calls it Breast carcinoma
• GO:0030212 (2 mentions) - the report calls it "Chondrocyte differentiation"; GO calls it hyaluronan metabolic process
• CL:0000120 (3 mentions) - the report calls it "Osteoblast"; CL calls it granule cell
• UBERON:0002413 (2 mentions) - the report calls it "Suggested UBERON: Vertebral column", "UBERON anatomical locations: Vertebral column"; UBERON calls it cervical vertebra**
• UBERON:0002445 (2 mentions) - the report calls it "Suggested UBERON: Long bone"; UBERON calls it ulnare
• UBERON:0003840 (2 mentions) - the report calls it "Epiphysis of long bone"; UBERON calls it hindlimb joint
• UBERON:0003841 (2 mentions) - the report calls it "Metaphysis of long bone"; UBERON calls it autopod joint
• UBERON:0002106 (2 mentions) - the report calls it "Suggested UBERON: Spleen"; UBERON calls it spleen
• UBERON:0002048 (1 mention) - the report calls it "Suggested UBERON: Lung"; UBERON calls it lung
• UBERON:0002414 (1 mention) - the report calls it "Suggested UBERON: Hyaline cartilage"; UBERON calls it lumbar vertebra
• CL:0000121 (1 mention) - the report calls it "Osteoclast"; CL calls it Purkinje cell
• NCIT:C77209 (2 mentions) - the report calls it "Suggested NCIT terms: Antibiotic Therapy"; NCIT calls it CHFR Gene
• NCIT:C15410 (2 mentions) - the report calls it "Suggested NCIT: Immunoglobulin Replacement Therapy"; NCIT calls it Biological Response Modifier Therapy
• NCIT:C15273 (2 mentions) - the report calls it "Suggested NCIT: Orthopedic Surgery Procedure", "NCIT interventions: Orthopedic Surgery Procedure"; NCIT calls it Longitudinal Study**
• NCIT:C15429 (2 mentions) - the report calls it "Suggested NCIT: Physical Therapy"; NCIT calls it Research Activity

Unresolved terms

These identifiers do not exist in an ontology that resolved other terms from the same prefix, so they were most likely invented:

• HP:0010572 (1 mention), reported as "Abnormal epiphysis morphology" - HP does not contain this term

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

• NCIT:C15410 (Biological Response Modifier Therapy) (2 mentions)

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• HP:0004322 (2 mentions) - the report calls it "Suggested HPO: Short stature"; HP calls it Short stature
• HP:0002721 (2 mentions) - the report calls it "Primary immunodeficiency"; HP calls it Immunodeficiency
• HP:0001263 (2 mentions) - the report calls it "Suggested HPO: Global developmental delay"; HP calls it Global developmental delay
• GO:0060350 (2 mentions) - the report calls it "Endochondral bone morphogenesis", "GO biological processes: Endochondral bone morphogenesis"; GO calls it endochondral bone morphogenesis**
• CL:0000138 (3 mentions) - the report calls it "Growth plate chondrocyte", "Chondrocyte", "CL cell types: Chondrocyte"; CL calls it chondrocyte**
• GO:1902554 (1 mention) - the report calls it "Protein kinase complex"; GO calls it serine/threonine protein kinase complex

Terms named inconsistently

The report gives these identifiers more than one name of its own:

• MONDO:0032571 - called "spondyloepimetaphyseal dysplasia, Krakow type", "Spondyloepimetaphyseal dysplasia, Krakow type"
• HP:0002650 - called "Spondyloepimetaphyseal dysplasia", "Key HPO terms:** Spondyloepimetaphyseal dysplasia"
• GO:0060350 - called "Endochondral bone morphogenesis", "GO biological processes:** Endochondral bone morphogenesis"
• CL:0000138 - called "Growth plate chondrocyte", "Chondrocyte", "CL cell types:** Chondrocyte"
• UBERON:0002413 - called "Suggested UBERON: Vertebral column", "UBERON anatomical locations:** Vertebral column"
• NCIT:C15273 - called "Suggested NCIT: Orthopedic Surgery Procedure", "NCIT interventions:** Orthopedic Surgery Procedure"

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: OMIM.